Vice President, Market Access – Theranostics

Clarity Pharmaceuticals is a leading ASX-listed clinical-stage radiopharmaceutical company developing theranostic (therapy and imaging) products based on our SAR Technology platform. Our mission is to develop next-generation radiopharmaceutical products that improve treatment outcomes for children and adults with cancer. Clarity has a diverse range of products in clinical trials addressing both large indications (prostate cancer and breast cancer) as well as rare and orphan indications (neuroendocrine tumors (NETs) and neuroblastoma).

Clarity Pharmaceuticals is a multidisciplinary team where all team members support each other in a variety of activities. We are looking for a team member who is motivated to take on new challenges and excited to help grow the company.

The Vice President, Market Access – Theranostics will define and lead the US market access strategy across Clarity’s integrated portfolio of PET diagnostics and radioligand therapeutics (RLTs). This role is responsible for end-to-end access strategy, including payer engagement, pricing and contracting, reimbursement strategy, patient access solutions, and field-based market access execution. The VP will play a critical leadership role in preparing Clarity for its first commercial launches, ensuring rapid, broad, and sustainable patient access.

Reporting directly to the Chief Commercial Officer, this position serves as a core member of the Commercial Leadership Team, shaping strategy and translating Clarity’s SAR-based theranostic innovation into commercially successful products.

• Develop and lead the market access strategy across radiopharmaceutical diagnostics and therapeutics, including pricing, contracting, and gross-to-net architecture
• Lead buy-and-bill reimbursement strategy for commercial and Medicare Part B coverage across freestanding and OPPS sites of service, navigating the complexities of Transitional Pass-Through (TPT) status, MUC, ASP, and other reimbursement models
• Lead integrated portfolio access strategy aligned to the theranostics model (diagnostic to therapy pathway)
• Build and maintain senior relationships with national and regional payers, CMS, MACs, and policy influencers
• Shape coverage policy, reimbursement pathways, and clinical pathway inclusion
• Monitor and proactively influence federal and state reimbursement policy, and radiopharmaceutical-specific payment evolution
• Provide executive insights on payer trends, risks, and access barriers

• Lead development of value-based pricing frameworks across the portfolio
• Oversee all payer and account contracting strategies across national and regional payers, IDNs, GPOs, hospital systems, and VA/DoD
• Define and deliver compelling value propositions, including health economic models, budget impact analyses, and evidence packages aligned to payer needs

• Lead market access launch readiness for near term (e.g., PSMA, SARTATE programs)
• Define access scenarios, pricing analyses, and reimbursement pathways pre-approval
• Partner with Clinical, Medical, and HEOR to ensure evidence generation supports access strategy, and early payer engagement informs development decisions
• Apply access expertise to early pipeline planning and lifecycle strategy

• Build and lead a field-based market access organization
• Ensure effective payer account management and reimbursement support capabilities
• Align with Account Management to ensure coverage translates to site-level access and utilization
• Drive strategic execution across health systems, urology/oncology networks, and imaging centers

• Establish…